Clinical trial
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
NCT03633617 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 24, 2018
- Completion date
- June 7, 2022
- Enrollment
- 321 (actual)
- Sites
- 95
Conditions
As the registry lists them; a condition with its own page is linked.